We have wholly-owned subsidiaries organized in Australia, Germany, the Netherlands, the United Kingdom and Taiwan. Our principal executive offices are located at 1600 District Avenue, Burlington, Massachusetts 01803 and our telephone number is (781) 557-4800. Table of Contents We believe our affordable holistic solution provides valuable clinical information and workflow efficiency that is attractive to any healthcare systems that seek to improve care at lower cost. These attributes also may allow the use o ...

业绩总结 - 公司宣布2023年收入为6,590万美元，超过了6,400万美元的收入指导[4] - Q4 2023营收为16.5美元，较Q4 2022的19.0美元下降13%[11] - 调整后的毛利率为56.6%，较Q4 2022的54.5%提高了2.1个百分点[11] 用户数据 - Butterfly设备被欧洲委员会认可为符合RoHS标准的铅污染手持压电器的可行替代品[21] - ScanLab™应用程序可帮助用户正确放置探头，并通过深度学习模型在实时成像中突出相关解剖结构[22] - 用户可获得有关探头定位和检查焦点的指导性上下文操作，并获得实时反馈指标[23] 未来展望 - 公司正在开拓印尼、菲律宾、马来西亚、孟加拉国和新加坡等新市场[21] - iQ+VET正在探索用于肥育牛健康的自动B线技术[24]

业绩总结 - 2023年第四季度总收入为1650万美元，较2022年的1900万美元下降，主要由于销量下降，部分抵消了价格上涨[1] - 美国销售额为1100万美元，略高于去年，主要由于ASP增加和软件订阅收入增加，部分抵消了电子商务销售下降[2] - 国际销售下降24%，至460万美元，主要是由于2022年的大订单未在2023年重复[3] - 公司总年度循环收入增长了4%[4] - 企业软件增长了35%，占总年度循环收入的41%[5] - 2023年总收入下降了10%，至65.9百万美元[6] - 调整后的毛利润率为57%，比2022年第四季度高出210个基点[7] - 调整后的EBITDA亏损为1570万美元，较2022年同期亏损减少[8] - 截至2023年12月31日，现金及现金等价物为1.39亿美元[9] - 2024年全年指导预期为低两位数的营收增长和EBITDA亏损为5000万至6000万美元[10] - 预计第一季度增长在中位数的个位数，随着iQ3的推出，增长将加速[11] - 2024年预计将实现低两位数的营收增长，由iQ3的推出和商业席位的投资驱动[12] 新产品和新技术研发 - Butterfly的iQ3在医疗专业人士中获得了更好的图像质量评价[13] - Butterfly在2023年成功部署了123个新账户，但并非所有交易都捆绑了软件和硬件[14] - iQ3具有iQ Slice功能，可以从单个位置捕获一系列图像[15] - Butterfly计划在2024年推动医学院课程中对Butterfly的采用，提供ScanLab等工具帮助学生练习超声波扫描技能[16] - Butterfly的AI驱动工具ScanLab已经免费提供给所有订阅用户，并已经有数千次下载[17] - Butterfly在兽医业务中继续探索在肉牛市场中使用自定义AI自动B-line工具的机会，这可能成为2024年的另一个增长驱动因素[18] - Butterfly预计今年将实现两位数的增长，正在开发第四代芯片，与DSMC合作[19] - Butterfly的超声波芯片将在未来成为医生在家中监测患者的工具，全球有超过1.5亿患有慢性疾病的患者[20] 市场扩张和并购 - Butterfly将于3月18日在纽约证券交易所举办投资者日活动，展示创新产品并讨论未来战略[21] - Butterfly已经推出了iQ3，并受到临床合作伙伴的好评，加入了许多机会到销售渠道中[22] - Butterfly的销售团队在美国医院市场的规模增加了30%至50%，并通过内部销售渠道和直销渠道共同合作[23] - 医疗系统中医生购买Butterfly产品的数量增加，有助于推动软件部署[24] - 公司计划在2024年增加资源，以提高直销团队的效率和收入[25] - 公司正在积极与政府和行业协会进行游说，以确保RoHS标准的执行[26] - 公司认为无论RoHS标准如何变化，都将有利于Butterfly产品[27]

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -75%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.13, delivering a surprise of 13.33%.Over the last four quarters, the company has su ...

Butterfly Network Reports Fourth Quarter 2023 Financial Results Completed Cost Savings and New Initiatives Position Butterfly for Growth Burlington, MA, and New York, NY, February 28, 2024 -- Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly" or the "Company"), an innovative digital health company transforming care through a unique combination of portable, semiconductor-based ultrasound technology, intuitive software, services and educational offerings that can make medical imaging more accessible than ever ...

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will present and host one-on-one investor meetings at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will prese ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange. During the event, Butterfly’s executive management team will present the Company’s product, software and services portfolio within the point-of-care ultrasound landscape, as well as its strategic ini ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, announced today the commercial launch of its third-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3™, which received FDA clearance last month. Butterfly iQ3 is powered by the Company’s most advanced semiconductor chip with a data tr ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, provided a business update today at the 42nd Annual J.P. Morgan Healthcare Conference. A webcast replay of the conference presentation can be viewed here, and will be available until February 10th, 2024. The presentation slide deck with animated videos can be accessed here ...

公司业务 - 公司是一家创新的数字健康企业，通过手持式全身超声波技术改变医疗[70] 设备数量变化 - 2023年9月30日，已完成的设备数量减少了2,290台，降低了40.1%[75] 收入构成 - 2023年9月30日，软件和其他服务占收入的比例为43.2%，比2022年同期增长了10.3个百分点[77] - 2023年9月30日，产品收入为8,753万美元，较2022年同期下降了33.5%[89] 费用变化 - 2023年9月30日，研发费用为12,130万美元，较2022年同期下降了45.0%[92] - 2023年第三季度，总体行政费用为11,560千美元，同比下降30.4%[95] - 2023年第三季度，其他费用为9,243千美元，同比增长219.1%[96] 前九个月财务表现 - 2023年前九个月，产品收入为29,874千美元，同比下降20.6%[97] - 2023年前九个月，软件和其他服务收入为19,510千美元，同比增长16.1%[97] - 2023年前九个月，产品成本为13,765千美元，同比下降29.3%[100] - 2023年前九个月，软件和其他服务成本为6,226千美元，同比增长24.0%[100] - 2023年前九个月，研发费用为44,409千美元，同比下降35.5%[102] - 2023年前九个月，销售和营销费用为28,776千美元，同比下降38.9%[103] - 2023年前九个月，总体行政费用为37,239千美元，同比下降31.1%[104] - 2023年前九个月，其他费用为17,848千美元，同比增长365.0%[105] 外汇风险 - 公司主要在美国进行业务，大部分交易以美元进行[125] - 公司未采用外汇套期保值策略，因此外汇风险有限，不会对财务报表产生重大影响[126]